Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a 'Locations' section with an 'Arizona' entry and removed the separate 'Arizona Locations' heading, altering how study sites are displayed.SummaryDifference0.2%

- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no impact on study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedRemoval of the government funding operating-status banner from the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check68 days agoChange DetectedThe page shows a visual redesign; core study details, eligibility criteria, and outcomes remain unchanged.SummaryDifference0.5%

- Check97 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference6%

- Check105 days agoChange DetectedUpgrade version from v3.0.2 to v3.1.0; no other content changes are specified.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.